Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Abeona Therapeutics Inc.NASDAQ: ABEO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 59.1%

Gross margin was 59.1% in Q1 FY2026. On a trailing-twelve-month basis it was 51.9%. Over 3 fiscal years it widened by 5.5 pp.

Context

  • Gross margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.1%+11.5 pp QoQ
Last fiscal yearDec 2025
73.7%— YoY
LTMMar 2026
51.9%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years+5.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
73.7%
Year-over-year change
—

Gross Margin vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 gross margin of 51.9% is the 5th highest of the 8 companies compared; the peer median is 74.5%.
  • Over three fiscal years its change of +5.5 pp compares with a peer median of -4.5 pp.
ABEO Competitors Peer median
Gross Margin for ABEO and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
PBYIPuma Biotechnology, Inc.LTM Mar 202674.5% +2.1 pp-1.3 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
SGMTSagimet Biosciences Inc.FY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ABEO) 74.5%-3.4 pp-4.5 pp

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3M1.41M3.5M05.82M
Cost of Revenue0450K1.61M2.91M1.53M
Gross Profit3M964K1.9M(2.91M)4.29M
Gross Margin100.0%68.2%54.1%—73.7%
Research & Development38.73M28.97M31.09M34.36M26.81M
Selling, General & Admin21.64M17.26M19M29.85M65.03M
Operating Expenses92.84M51.88M49.03M61.3M93.74M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
EBITDA(76.82M)(34.38M)(50.57M)(56.62M)78.59M
EBITDA Margin-2560.5%-2431.6%-1444.9%—1350.3%
Operating Income(89.84M)(50.92M)(47.14M)(64.21M)(89.45M)
Operating Margin-2994.5%-3600.8%-1346.7%—-1536.9%
Interest Income40K431K2.12M4.25M5.56M
Interest Expense3.66M736K418K4.21M3.74M
Other Income / Expenses4.9M11.22M(7.05M)477K160.73M
Income Before Tax(84.94M)(39.7M)(54.19M)(63.73M)71.28M
Pre-Tax Margin-2831.2%-2807.4%-1548.2%—1224.8%
Income Tax Expense0000100K
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Net Margin-2831.2%-2807.4%-1548.2%—1223.1%
EPS (Basic)(21.50)(5.53)(2.53)(1.55)1.34
EPS (Diluted)(21.50)(5.53)(2.53)(1.55)1.01
Weighted Avg Shares3.94M7.86M21.38M41.05M52.95M
Weighted Avg Shares (Diluted)3.94M7.86M21.38M41.05M66.14M

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.